Citigroup
DYN icon

Citigroup’s Dyne Therapeutics DYN Stock Holding History

Citigroup’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$685K Buy
37,797
+1,140
+3% +$19.7K ﹤0.01% 3358
2025
Q4 		$717K Buy
36,657
+3,272
+10% +$62K ﹤0.01% 3359
2025
Q3 		$422K Sell
33,385
-28,142
-46% -$321K ﹤0.01% 3661
2025
Q2 		$586K Sell
61,527
-133,428
-68% -$1.47M ﹤0.01% 3533
2025
Q1 		$2.04M Buy
194,955
+52,038
+36% +$744K ﹤0.01% 2691
2024
Q4 		$3.37M Buy
142,917
+78,479
+122% +$2.32M ﹤0.01% 2353
2024
Q3 		$2.31M Buy
64,438
+27,725
+76% +$1.1M ﹤0.01% 2532
2024
Q2 		$1.3M Sell
36,713
-263,414
-88% -$7.65M ﹤0.01% 2710
2024
Q1 		$8.52M Buy
300,127
+228,523
+319% +$5.17M 0.01% 1340
2023
Q4 		$952K Buy
71,604
+9,709
+16% +$94.8K ﹤0.01% 2861
2023
Q3 		$555K Buy
61,895
+11,508
+23% +$124K ﹤0.01% 2980
2023
Q2 		$567K Buy
50,387
+45,942
+1,034% +$542K ﹤0.01% 3286
2023
Q1 		$51.2K Sell
4,445
-5,724
-56% -$74.3K ﹤0.01% 4255
2022
Q4 		$118K Sell
10,169
-116,409
-92% -$1.35M ﹤0.01% 3957
2022
Q3 		$1.61M Sell
126,578
-276,078
-69% -$3.17M ﹤0.01% 2321
2022
Q2 		$2.77M Buy
402,656
+395,230
+5,322% +$2.72M ﹤0.01% 1879
2022
Q1 		$72K Sell
7,426
-6,493
-47% -$55.3K ﹤0.01% 4573
2021
Q4 		$165K Buy
13,919
+10,128
+267% +$142K ﹤0.01% 4451
2021
Q3 		$62K Buy
3,791
+1,913
+102% +$33.9K ﹤0.01% 4626
2021
Q2 		$40K Buy
1,878
+810
+76% +$15.2K ﹤0.01% 4923
2021
Q1 		$17K Sell
1,068
-1,591
-60% -$30.8K ﹤0.01% 5339
2020
Q4 		$56K Buy
+2,659
New +$52.6K ﹤0.01% 5954

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Citigroup's DYN Position: Q1 2026 in Review

Citigroup increased its Dyne Therapeutics (DYN) stake by 3.1% in Q1 2026, buying an estimated $19.7K and bringing the position to 37,797 shares worth $685K. The position accounts for ﹤0.01% of the portfolio, ranked #3358.

Citigroup first reported a position in DYN in Q4 2020 and has held it in 22 quarters since. The position peaked at $8.52M in Q1 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Citigroup held 37,797 shares of Dyne Therapeutics worth $685K as of Q1 2026.
  • Citigroup bought 1,140 Dyne Therapeutics shares in Q1 2026, an estimated $19.7K.
  • Dyne Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3358 holding.
  • Citigroup first reported a position in Dyne Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Citigroup's Dyne Therapeutics position peaked at $8.52M in Q1 2024.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.